Viking Therapeutics' GLP 1 pill candidate shows promise in latest study MM+M Medical Marketing and Media Copper Peptide GHK Cu for Sale Stanford Advanced Materials An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed. An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed., You thought Ozempic was big? Just wait. The next generation of weight loss medications is already in clinical trials oral pills, monthly injections, and even triple action drugs that may work better than